-
What is the Jynneos vaccine and how does it work?
The Jynneos vaccine is designed to protect against mpox, previously known as monkeypox. It works by stimulating the immune system to recognize and fight the virus. The vaccine has been prequalified by the WHO, allowing for its procurement by organizations like GAVI and UNICEF, which will facilitate its distribution in affected regions.
-
Why is the mpox outbreak particularly severe in the Democratic Republic of the Congo?
The mpox outbreak in the Democratic Republic of the Congo is particularly severe due to a combination of factors, including high transmission rates and a significant number of cases among children. Nearly 70% of reported cases are in individuals under 15, highlighting the urgent need for vaccination and public health interventions.
-
What organizations are involved in the vaccination efforts?
Key organizations involved in the vaccination efforts include the World Health Organization (WHO), GAVI, and UNICEF. These organizations are working together to ensure the Jynneos vaccine is distributed effectively to combat the ongoing outbreak in Africa, particularly in the DRC.
-
How will this vaccine approval affect public health in Africa?
The approval of the Jynneos vaccine is expected to significantly improve public health in Africa by providing a crucial tool to combat the mpox outbreak. With vaccination efforts set to begin on October 2, 2024, it is hoped that the vaccine will help reduce transmission rates and protect vulnerable populations, especially children.
-
What are the next steps for vaccination in Africa?
Following the WHO's approval, vaccination efforts are scheduled to commence on October 2, 2024. Organizations like GAVI and UNICEF will play a vital role in the distribution of the Jynneos vaccine, and there are plans for Bavarian Nordic to deliver an additional 50 million doses over the next 12-18 months, pending regulatory approvals.
-
What is the current status of mpox cases in Africa?
As of now, the Democratic Republic of the Congo has reported over 25,000 cases and 700 deaths from mpox this year alone. The WHO declared a global health emergency in August 2024 due to the rising cases, emphasizing the urgent need for effective vaccination and public health measures.